» Articles » PMID: 36675123

Antibacterial Activity of Ebselen

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jan 21
PMID 36675123
Authors
Affiliations
Soon will be listed here.
Abstract

Ebselen is a low-molecular-weight organoselenium compound that has been broadly studied for its antioxidant, anti-inflammatory, and cytoprotective properties. These advantageous properties were initially associated with mimicking the activity of selenoprotein glutathione peroxidase, but the biomedical impact of this compound appear to be far more complex. Ebselen serves as a substrate or inhibitor with multiple protein/enzyme targets, whereas inhibition typically originates from the covalent modification of cysteine residues by opening the benzisoselenazolone ring and S-Se bond formation. The inhibition of enzymes of various classes and origins has been associated with substantial antimicrobial potential among other activities. In this contribution, we summarize the current state of the art regarding the antibacterial activity of ebselen. This activity, alone and in combination with commercial pharmaceuticals, against pathogens, including those resistant to drugs, is presented, together with the molecular mechanism behind the reactivity. The specific inactivation of thioredoxin reductase, bacterial toxins, and other resistance factors is considered to have certain therapeutic implications. Synergistic action and sensitization to common antibiotics assisted with the use of ebselen appear to be promising directions in the treatment of persistent infections.

Citing Articles

Selenocompounds as Potent Efflux Pump Inhibitors on Gram-positive Bacteria.

Kincses A, Szemeredi N, Benito-Lama M, Dozsai D, Csonka A, Dominguez-Alvarez E ChemMedChem. 2024; 20(2):e202400691.

PMID: 39565046 PMC: 11733404. DOI: 10.1002/cmdc.202400691.


Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis.

Dong C, Wang Y, Cai Y, Wu Y, Chen W, Wang L Drug Des Devel Ther. 2024; 18:3811-3824.

PMID: 39219694 PMC: 11365518. DOI: 10.2147/DDDT.S475535.


Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning.

Glajzner P, Bernat A, Jasinska-Stroschein M Front Pharmacol. 2024; 15:1397602.

PMID: 38910882 PMC: 11193365. DOI: 10.3389/fphar.2024.1397602.


Exploring Immune Redox Modulation in Bacterial Infections: Insights into Thioredoxin-Mediated Interactions and Implications for Understanding Host-Pathogen Dynamics.

Dagah O, Silaa B, Zhu M, Pan Q, Qi L, Liu X Antioxidants (Basel). 2024; 13(5).

PMID: 38790650 PMC: 11117976. DOI: 10.3390/antiox13050545.


Novel Therapeutic Hybrid Systems Using Hydrogels and Nanotechnology: A Focus on Nanoemulgels for the Treatment of Skin Diseases.

Sghier K, Mur M, Veiga F, Paiva-Santos A, Pires P Gels. 2024; 10(1).

PMID: 38247768 PMC: 10815052. DOI: 10.3390/gels10010045.


References
1.
Aliashkevich A, Cava F . LD-transpeptidases: the great unknown among the peptidoglycan cross-linkers. FEBS J. 2021; 289(16):4718-4730. DOI: 10.1111/febs.16066. View

2.
Sies H . Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic Biol Med. 1993; 14(3):313-23. DOI: 10.1016/0891-5849(93)90028-s. View

3.
Nozawa R, Yokota T, Fujimoto T . Susceptibility of methicillin-resistant Staphylococcus aureus to the selenium-containing compound 2-phenyl-1,2-benzoisoselenazol-3(2H)-one (PZ51). Antimicrob Agents Chemother. 1989; 33(8):1388-90. PMC: 172662. DOI: 10.1128/AAC.33.8.1388. View

4.
Macegoniuk K, Grela E, Palus J, Rudzinska-Szostak E, Grabowiecka A, Biernat M . 1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors. J Med Chem. 2016; 59(17):8125-33. DOI: 10.1021/acs.jmedchem.6b00986. View

5.
Maqbool I, Ponniresan V, Govindasamy K, Prasad N . Understanding the survival mechanisms of Deinococcus radiodurans against oxidative stress by targeting thioredoxin reductase redox system. Arch Microbiol. 2019; 202(9):2355-2366. DOI: 10.1007/s00203-019-01729-6. View